Researchers found that circulating tumor DNA testing could identify which older patients with estrogen receptor–positive breast cancer are less likely to respond to hormone therapy alone.
The integrated testing approach combines genomic profiling with immunohistochemistry to support faster treatment decisions for advanced-stage cancer patients.
The G4X system can analyze 128 samples per run with 500-plex RNA and 18-plex protein capabilities, targeting translational research and clinical applications.
Bridge Capture, a targeted NGS method, showed higher sensitivity for detecting rare ctDNA variants than two leading liquid biopsy assays, according to research in The Journal of Molecular Diagnostics.
Read More
Weill Cornell Medicine researchers report a whole-genome sequencing algorithm may identify more patients for PARP inhibitor cancer therapies than current commercial tests, according to a study in Communications Medicine.
Read More
New kit cuts sample-to-result time to 75 minutes while maintaining sensitivity for drug metabolism studies.
Read More
Researchers have developed a tool that measures gut-specific inflammation, potentially improving IBD diagnosis and monitoring.
Read More
University of Washington researchers find rapid test could improve treatment rates but may face implementation barriers due to reimbursement challenges.
Read More
The collaboration integrates AI-driven blood testing with a nationwide hepatology specialist network to reduce diagnostic delays.
Read More
Partnership with Certest Biotec adds respiratory and STI molecular diagnostic panels for European laboratories.
Read More
The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers, according to the company.
Read More
The version 2.0 systems feature increased throughput, expanded assay flexibility, and the ability to run up to six unique assays per run.
Read More
Hospital teams can trial the company’s BSI/AMR test and preview the LiDia-SEQ system ahead of commercial launch.
Read More
The precision medicine company now has 57 approvals in the US and 43 in Japan for its FoundationOne CDx and FoundationOne Liquid CDx tests.
Read More
The collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.
Read More
The platform features enhanced speed and digital connectivity for liquid biopsy applications, with commercial release planned for mid-2026.
Read More
UMBS-seq preserves DNA integrity while maintaining accuracy for cancer biomarker detection in liquid biopsies and tissue samples.
Read More
The proposed order would shift these test systems to Class II with special controls, replacing the current PMA requirement for companion diagnostics and related oncology assays.
Read More